Received Mar 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | — | — |
SARS-CoV-2 infection; SARS-CoV-2 infection; This is a literature report for the following literature source(s). An adult patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "solid organ transplant recipients" (unspecified if ongoing), notes: with a functional graft. The patient's concomitant medications were not reported. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "SARS-CoV-2 infection". Additional information: the patient age was over 18 years. SOT recipients with a functional graft, recipients beyond one month of transplant. At least one-month post second dose of BNT162b2 vaccine. The patient received the 3rd dose of BNT162b2 then got SARS-COV-2 infection before 6th month blood draw after dose 3.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event lack of effect/drug ineffective (CoVID-19) with the suspect product BNT162B2 cannot be fully excluded. Linked Report(s) : US-PFIZER INC-PV202500025503 Same article/event and different patient;
Medical History/Concurrent Conditions: Solid organ transplant (with a functional graft)